Telitacicept
BJ-2021-235
Phase 2 mab active
Quick answer
Telitacicept for Connective Tissue Diseases is a Phase 2 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Connective Tissue Diseases
- Phase
- Phase 2
- Modality
- mab
- Status
- active